Medikamentöse Therapie der amyotrophen Lateralsklerose: ein Update

Pharmacological treatment of amyotrophic lateral sclerosis: an update

DGNeurologie volume 4, pages80–86(2021)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

US$ 39.95

Tax calculation will be finalised during checkout.

Literatur

  1. 1.

    van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH et al (2017) Amyotrophic lateral sclerosis. Lancet 390(10107):2084–2098

    Article  Google Scholar 

  2. 2.

    Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O (2003) Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000. J Neurol Neurosurg Psychiatry 74(9):1258–1261

    CAS  Article  Google Scholar 

  3. 3.

    Ludolph AC, Dorst J, Dreyhaupt J, Weishaupt JH, Kassubek J, Weiland U et al (2020) Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. Ann Neurol 87(2):206–216

    Article  Google Scholar 

  4. 4.

    Wills AM, Hubbard J, Macklin EA, Glass J, Tandan R, Simpson EP et al (2014) Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 383(9934):2065–2072

    CAS  Article  Google Scholar 

  5. 5.

    Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ (2006) Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 5(2):140–147

    Article  Google Scholar 

  6. 6.

    Zwicker J, Qureshi D, Talarico R, Bourque P, Scott M, Chin-Yee N et al (2019) Dying of amyotrophic lateral sclerosis: health care use and cost in the last year of life. Neurology 93(23):e2083–e93

    Article  Google Scholar 

  7. 7.

    Wobst HJ, Mack KL, Brown DG, Brandon NJ, Shorter J (2020) The clinical trial landscape in amyotrophic lateral sclerosis - past, present, and future. Med Res Rev 40(4):1352–1384

    CAS  Article  Google Scholar 

  8. 8.

    Writing Group, Edaravone (MCI-186) ALS 19 Study Group (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16(7):505–512. https://doi.org/10.1016/S1474-4422(17)30115-1

    Article  Google Scholar 

  9. 9.

    Ludolph AC, Schuster J, Dorst J, Dupuis L, Dreyhaupt J, Weishaupt JH et al (2018) Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol 17(8):681–688

    CAS  Article  Google Scholar 

  10. 10.

    Dorst J, Kuhnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC (2011) Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol 258(4):613–617

    CAS  Article  Google Scholar 

  11. 11.

    Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S et al (2020) Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med 383(10):919–930

    CAS  Article  Google Scholar 

  12. 12.

    Riva N, Mora G, Soraru G, Lunetta C, Ferraro OE, Falzone Y et al (2019) Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 18(2):155–164

    CAS  Article  Google Scholar 

  13. 13.

    Young CA, Ellis C, Johnson J, Sathasivam S, Pih N (2011) Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database Syst Rev 5:CD6981

    Google Scholar 

  14. 14.

    Bedlack RS, Pastula DM, Hawes J, Heydt D (2009) Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease. Amyotroph Lateral Scler 10(4):210–215

    Article  Google Scholar 

  15. 15.

    Weiss MD, Macklin EA, Simmons Z, Knox AS, Greenblatt DJ, Atassi N et al (2016) A randomized trial of mexiletine in ALS: safety and effects on muscle cramps and progression. Neurology 86(16):1474–1481

    CAS  Article  Google Scholar 

  16. 16.

    Gladman M, Dehaan M, Pinto H, Geerts W, Zinman L (2014) Venous thromboembolism in amyotrophic lateral sclerosis: a prospective study. Neurology 82(19):1674–1677

    Article  Google Scholar 

  17. 17.

    EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S, Borasio GD, de Carvalho M et al (2012) EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)—revised report of an EFNS task force. Eur J Neurol 19(3):360–375

    Article  Google Scholar 

Download references

Danksagung

Andreas Hermann wird unterstützt durch die Hermann und Lilly Schilling-Stiftung für medizinische Forschung im Stifterverband.

Author information

Affiliations

  1. Sektion für Translationale Neurodegeneration „Albrecht Kossel“, Klinik und Poliklinik für Neurologie, Universitätsmedizin Rostock, Gehlsheimer Straße 20, 18147, Rostock, Deutschland

    Prof. Dr. Dr. A. Hermann & Prof. Dr. J. Prudlo

  2. Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Standort Rostock/Greifswald, 18147, Rostock, Deutschland

    Prof. Dr. Dr. A. Hermann & Prof. Dr. J. Prudlo

Authors
  1. Prof. Dr. Dr. A. Hermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. J. Prudlo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Prof. Dr. Dr. A. Hermann.

Ethics declarations

Interessenkonflikt

Die Universitätsmedizin Rostock nimmt an Studien zur Prüfung neuer Medikamente zur Behandlung der ALS teil. A. Hermann war in der Vergangenheit beratend und vortragend tätig für Firmen, die Medikamente zur Behandlung der ALS herstellen bzw. vertreiben (Desitin, BIOGEN). J. Prudlo hielt 2018 und 2019 Vorträge auf ALS-Expertenmeetings der Firma Desitin.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

F. Block, Schwerin

S.G. Meuth, Münster

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hermann, A., Prudlo, J. Medikamentöse Therapie der amyotrophen Lateralsklerose: ein Update. DGNeurologie 4, 80–86 (2021). https://doi.org/10.1007/s42451-021-00303-z

Download citation